Nektar Therapeutics (NKTR) Capital Expenditures Growth (3y) (2013 - 2026)
Powered by 
Analysis
Nektar Therapeutics (NKTR) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 23.48% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 63.07% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -45.93% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -40.95% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 29.63% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 60.74% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.08% |
| 10 | Nektar Therapeutics | 2.45 Bn | 1.77 Bn | 3.04 Mn | -16.59% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16.59% |
| Mar 31, 2026 | -65.36% |
| Dec 31, 2025 | -67.24% |
| Sep 30, 2025 | -14.28% |
| Jun 30, 2025 | -63.80% |
| Mar 31, 2025 | -92.19% |
| Dec 31, 2024 | -57.30% |
| Sep 30, 2024 | -39.01% |
| Jun 30, 2024 | -61.58% |
| Mar 31, 2024 | -62.07% |
| Dec 31, 2023 | -48.69% |
| Sep 30, 2023 | -74.15% |
| Jun 30, 2023 | -60.82% |
| Mar 31, 2023 | -21.64% |
| Dec 31, 2022 | -48.14% |
| Sep 30, 2022 | -67.60% |
| Jun 30, 2022 | -59.39% |
| Mar 31, 2022 | -9.38% |
| Dec 31, 2021 | -12.12% |
| Sep 30, 2021 | 17.24% |